The mammalian target of rapamycin (mTOR), a phosphoinositide 3-kinase-related protein kinase, controls cell growth in response to nutrients and growth factors and is frequently deregulated in cancer.

The mammalian target of rapamycin (mTOR) is a highly conserved kinase that belongs to the phosphoinositide 3-kinase-related protein kinases (PIKK) family. mTOR participates in two distinct complexes, ...

A large, multi-institution study led by a Brown University physician-scientist could have important implications for the ...

Cytotoxic T lymphocytes play a crucial role in adaptive immunity, primarily defending against tumors and viruses. These cells develop within the thymus gland and undergo rapid activation upon ...

Oncotelic Therapeutics Inc. 's (OTCQB: OTLC) Sapu Nano joint venture is making progress with Sapu003, its intravenous Deciparticle formulation of everolimus, the powerful drug to fight cancer and ...

A new article reflects on how two generations of scientists reshaped thinking on aging, linking hormonal regulation in the ...

Angelini Pharma has licensed a preclinical-stage mTOR inhibitor from South Korean biotech Sovargen with potential for genetic forms of epilepsy and other brain disorders. The $550 million-plus deal ...

Interrupting one function of a protein that plays a key role in cell signaling could enable the development of new cancer ...